Evidence map›Paper›PMID 39322715›Full record

ArticleLeukemia2024

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials.

Georg Lenz, Hervé Tilly, Marita Ziepert, Bettina Altmann, Charles Herbaux, Fabian Frontzek, Maike Nickelsen, Calvin Lee, Jamie Hirata, Deniz Sahin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Integration of [Leukemia · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Georg LenzMedical Department A, University Hospital Münster, Münster, Germany. georg.lenz@ukmuenster.de.ORCID http://orcid.org/0000-0002-4728-1693
Hervé TillyCentre Henri-Becquerel and University of Rouen, Rouen, France.
Marita ZiepertInstitute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany.
Bettina AltmannInstitute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany.
Charles HerbauxUniversity of Montpellier, Montpellier, France.ORCID http://orcid.org/0000-0003-4910-476X
Fabian FrontzekMedical Department A, University Hospital Münster, Münster, Germany.
Maike NickelsenOnkologie Lerchenfeld, Hamburg, Germany.
Calvin LeeGenentech Inc., South San Francisco, CA, USA.
Jamie HirataGenentech Inc., South San Francisco, CA, USA.
Deniz SahinF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Saibah ChohanHoffmann-La Roche Ltd, Mississauga, ON, Canada.
Connie Lee BatleviGenentech Inc., South San Francisco, CA, USA.
Mark YanHoffmann-La Roche Ltd, Mississauga, ON, Canada.
Franck MorschhauserUniversity of Lille, Centre Hospitalier Universitaire, Lille, France.
Norbert SchmitzMedical Department A, University Hospital Münster, Münster, Germany.ORCID http://orcid.org/0000-0003-4938-7528

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39322715
PMCPMC11588652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.